-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
[Pharmaceutica.
com Company News] Taking patients as the center and clinical needs as the orientation, Fosun Pharma has continuously enriched its innovative product pipeline through diversified and multi-level cooperation models such as independent research and development, cooperative development, licensing introduction, and deep incubati.
The author was informed that Fosun Pharma has reached a number of cooperations again recent.
On June 27, Fosun Pharma announced that it has reached a cooperation with Amgen on the commercialization of Amgen's two innovative drugs in China (excluding Hong Kong, Macao and Taiwa.
The two innovative drugs are Otaila and Parsab.
According to the industry, the cooperation will enable Amgen to leverage Fosun Pharma's commercial capabilities in China to bring these two products to China's psoriasis and chronic kidney disease patients at a faster pa.
According to the announcement, Fosun Pharma USA, a subsidiary of Fosun Pharma, shall pay Kai Pharma, a subsidiary of Amgen Holdings, up to US$47 million in the down payment and regulatory milestones for the licensed products, and pay sales milestones and other payments according to the agreement, of which the down payment is US$4,30 USD 10,000: payable within 30 working days after the agreement takes effe.
According to the data, Otai was approved by the National Medical Products Administration in August 2021 for the treatment of adult patients with moderate to severe plaque psoriasis who are eligible for phototherapy or systemic thera.
Parsabiv is a novel calcium-sensing receptor agonist, which was approved by the European Medicines Agency and the US Food and Drug Administration in November 2016 and February 2017 for the treatment of adult chronic kidney disease patients undergoing hemodialysis of secondary hyperparathyroidism (SHP.
Amgen said that by licensing its two products, the two parties can combine their advantages and synergize to ensure that innovative drugs can benefit more patients, while also enabling Amgen to focus on the core disease areas of cardiovascular and bone health in Chi.
It is understood that Fosun Pharma has been deeply engaged in the fields of autoimmune diseases and chronic kidney diseases including psoriasis for many yea.
It said that in the future, it will work together with Amgen to give full play to its advantages in these fields and improve the availability of medicines for patien.
sex, helping them benefit from these innovative medicines as early as possible, control disease and improve quality of li.
In addition to the above cooperation, Fosun Pharma also announced recently that on June 28, Henlius, a holding subsidiary of the company, signed a "Cooperation and License Agreement" with Palle.
1) Palleon's research product bifunctional HER2-sialidase fusion protein (ie "licensed product"), and (2) another tumor-related target sialidase bifunctional fusion protein to be jointly developed by both parties (ie "co-developed.
products”) in the development, production and commercialization in the field .
for the treatment of human disease.
The data show that the bifunctional HER2-sialidase fusion protein is an antibody-sialidase fusion protein that targets HER2 independently developed by Palle.
Fosun Pharma stated that this cooperation will help enrich the Group's product pipeline in the field of tumor treatment and enhance the Group's comprehensive market competitiveness in the field of tumor treatme.
Disclaimer: Under no circumstances does the information or opinions expressed in this article constitute investment advice to anyo.
Click to enter the exhibition page
com Company News] Taking patients as the center and clinical needs as the orientation, Fosun Pharma has continuously enriched its innovative product pipeline through diversified and multi-level cooperation models such as independent research and development, cooperative development, licensing introduction, and deep incubati.
The author was informed that Fosun Pharma has reached a number of cooperations again recent.
On June 27, Fosun Pharma announced that it has reached a cooperation with Amgen on the commercialization of Amgen's two innovative drugs in China (excluding Hong Kong, Macao and Taiwa.
The two innovative drugs are Otaila and Parsab.
According to the industry, the cooperation will enable Amgen to leverage Fosun Pharma's commercial capabilities in China to bring these two products to China's psoriasis and chronic kidney disease patients at a faster pa.
According to the announcement, Fosun Pharma USA, a subsidiary of Fosun Pharma, shall pay Kai Pharma, a subsidiary of Amgen Holdings, up to US$47 million in the down payment and regulatory milestones for the licensed products, and pay sales milestones and other payments according to the agreement, of which the down payment is US$4,30 USD 10,000: payable within 30 working days after the agreement takes effe.
According to the data, Otai was approved by the National Medical Products Administration in August 2021 for the treatment of adult patients with moderate to severe plaque psoriasis who are eligible for phototherapy or systemic thera.
Parsabiv is a novel calcium-sensing receptor agonist, which was approved by the European Medicines Agency and the US Food and Drug Administration in November 2016 and February 2017 for the treatment of adult chronic kidney disease patients undergoing hemodialysis of secondary hyperparathyroidism (SHP.
Amgen said that by licensing its two products, the two parties can combine their advantages and synergize to ensure that innovative drugs can benefit more patients, while also enabling Amgen to focus on the core disease areas of cardiovascular and bone health in Chi.
It is understood that Fosun Pharma has been deeply engaged in the fields of autoimmune diseases and chronic kidney diseases including psoriasis for many yea.
It said that in the future, it will work together with Amgen to give full play to its advantages in these fields and improve the availability of medicines for patien.
sex, helping them benefit from these innovative medicines as early as possible, control disease and improve quality of li.
In addition to the above cooperation, Fosun Pharma also announced recently that on June 28, Henlius, a holding subsidiary of the company, signed a "Cooperation and License Agreement" with Palle.
1) Palleon's research product bifunctional HER2-sialidase fusion protein (ie "licensed product"), and (2) another tumor-related target sialidase bifunctional fusion protein to be jointly developed by both parties (ie "co-developed.
products”) in the development, production and commercialization in the field .
for the treatment of human disease.
The data show that the bifunctional HER2-sialidase fusion protein is an antibody-sialidase fusion protein that targets HER2 independently developed by Palle.
Fosun Pharma stated that this cooperation will help enrich the Group's product pipeline in the field of tumor treatment and enhance the Group's comprehensive market competitiveness in the field of tumor treatme.
Disclaimer: Under no circumstances does the information or opinions expressed in this article constitute investment advice to anyo.
Click to enter the exhibition page
